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Programmed cell death or apoptosis is of fundamental 
importance to cancer as it both limits tumorigenesis and 
is also triggered by many cancer chemotherapeutics [1, 
2]. Importantly, cancer cells often acquire mutations 
that compromise the apoptotic process, allowing these 
cells to both escape normal growth constraints and to 
become resistant to many anti-cancer drugs, resulting in 
the emergence of drug-resistant malignancies [3]. Thus 
discovering how apoptosis is regulated and why it fails 
in cancer is central to both understanding cancer 





































































as  TNFα by  upregulating  known  anti‐apoptotic  genes,  NF‐κB  has  also  been  proposed  to  be  required  for  p53‐induced
apoptosis  in  transformed  cells.  However,  the  involvement  of  NF‐κB  in  this  process  is  poorly  understood.  Here  we
investigate  this  mechanism  and  show  that  in  transformed  MEFs  lacking  NF‐κB  (p65









chemo-resistant cancers. Many proteins involved in the 
apoptotic process have been identified [4], including 
proteins of the p53 family, a tumour suppressor whose 
function is compromised in many cancer cells.  p53 is a 
well established tumour suppressor and key regulator of 
apoptosis that is induced by both oncogenes and 
chemotherapeutic drugs (genotoxins) that damage DNA 
[5]. p53 induces apoptosis predominantly by increasing 
expression of genes of the Bcl-2 family, such as Bax, 
PUMA and Noxa, that trigger cytochrome c release 
from mitochondria into the cytosol [6]. Cytosolic 
cytochrome c binds to Apaf-1, which complexes with, 
and activates the initiator caspase-9. This leads to the 
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death [7, 8].  
 
p53 is the first member of a closely related family 
which includes the proteins p63 and p73.  However, p63 
and p73 are present in multiple isoforms and their role 
in tumour formation and apoptosis control is not as well 
defined as it is for p53.  Mouse knock out (K.O.) studies 
revealed unexpected functional diversity among these 
proteins.  p63 and p73 K.O. mice exhibit severe 
developmental abnormalities and no increased tumour 
formation, whereas p53 K.O.  mice show no develop-
mental defect but early appearance of tumours (for 
review see [9]).  Recent long-term studies in mice, 
however, support a direct role of p63 and p73 on 
tumour suppression.  A recent K.O. mouse specific for 
the TA isoform of p73, however, shows an intermediate 
phenotype between the full p73 
-/- and p53 
-/- regarding 
tumour formation, supporting a role of p73 in tumour 
suppression [10].  Additionally, p63 and p73 can 
cooperate with p53 in tumour suppression [11]. 
 
Functionally, p73α and p73β closely resemble the 
biological activity of p53, including the ability to induce 
apoptosis.  p73β, and less efficiently p73α, bind to 
canonical p53 elements in the DNA and transactivate 
many p53 dependent promoters [12].   
 
Recently, the transcription factor NF-κB, which clearly 
inhibits apoptosis induced by some death signals [13, 
14], was proposed to play a role in driving p53-
mediated apoptosis in transformed cells [15]. It has also 
been suggested a proapoptotic role in cerebral ischemia 
through p65 (RelA) containing complexes [16, 17]. The 
canonical NF-κB complex is a heterodimer of p50 and 
p65, which accounts for the majority of the NF-κB 
complexes found in non-immune cells. NF-κB is 
activated by a variety of signals, including pro-
inflammatory and stress factors, that cause phos-
phorylation of the IκB inhibitory proteins by the IκB-
kinase complex. Phosphorylation marks IκB for 
ubiquitinylation and proteasomal degradation, allowing 
NF-κB complexes to localize to the nucleus where they 
affect transcription (for review see [18]).  The idea that 
NF-κB is pro-apoptotic is, however, controversial for 
several reasons. Elevated NF-κB activity is associated 
with increased tumorigenesis [19] and decreasing its 
activity can inhibit tumorigenesis [20]. Consistent with 
these observations is the fact that several anti-apoptotic 
genes are NF-κB targets and NF-κB activation can 
protect cells from apoptosis, therefore increasing 
oncogenic potential [21-23]. Indeed, NF-κB activation 
can reduce p53 stabilization triggered by chemo-
therapeutics [24]. However, the effect of NF-κB on 
tumorigenesis and apoptosis appears to be context-
dependent because inactivation of NF-κB can promote 
tumorigenesis [25] and prevent both p53- [15] and 
chemotherapy-induced apoptosis [26, 27]. In addition, 
two genes deregulated in human tumours, β-catenin and 
HSCO, inhibit NF-κB activity by sequestering NF-κB 
in the cytosol, blocking Fas-induced [28] and p53-
induced apoptosis [29]. NF-κB is also implicated in 
apoptosis induced by growth factor withdrawal, viruses 
and ischemia [30-34].  Why NF-κB might be required 
for p53-induced apoptosis is unknown. To further 
evaluate the idea that NF-κB is pro-apoptotic, we chose 
to investigate genotoxin-dependent apoptosis in cells 
lacking p65.  By using a combination of approaches, we 
show that in the absence of p65, DNA damage-induced 
expression of a pro-apoptotic BH3-only protein, Noxa, 
is compromised.  Although p53 present in the immor-
talized p65 null cells used in our study is a non-
functional mutant, our experiments show that DNA 
damage-induced activation of p73 depends on the 
presence of p65.  Furthermore, p73 regulates the 
expression of Noxa through the p53 element in its 
promoter.  Thus in the absence of p53, NF-κB controls 
the DNA damage-induced cell death through the 




p65 null MEFs are resistant to genotoxin-induced 
death 
 
To address how NF-κB deficiency alters p53-dependent 
apoptosis in transformed cells we examined the ability 
of p65 null MEFs transformed with the adenoviral 
oncogene E1A to undergo apoptosis induced by 
genotoxic agents. As a control for these studies NF-κB 
function was reconstituted by retroviral gene transfer of 
p65 (Figure 1A). To control for this manipulation p65 
null MEFs were mock infected with an empty retroviral 
vector.  Thus these two cell types differ only in p65 
expression and are a closer genetic match than available 
wild type MEFs. When the sensitivity to apoptosis 
induced by genotoxic agents of the p65 null and 
reconstituted MEFs was compared cells lacking p65 
were resistant to both a topoisomerase inhibitor 
(etoposide) and UV-irradiation, two DNA-damaging 
agents that activate cell death. However, reconstitution 
of p65 greatly increased sensitivity to induction of 
apoptosis by these agents.  Apoptosis was assessed by 
the appearance of cells with hypodiploid DNA content 
(Figure 1B) and also by activation of caspases (Figure 
1C), therefore two criteria confirmed that loss of p65 
confers resistance to genotoxin-induced apoptosis. In 
contrast, p65 null cells are extremely sensitive to TNFα 
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resistance, consistent with the p65-dependent activation 





















































p65 null MEFs retain functional apoptotic 
machinery 
 
To investigate what stage of the genotoxin-induced 
pathway was compromised by loss of p65, we first 
checked the expression of several key components of 
the apoptotic pathway (Figure 2A).  mRNA level for 
caspases-3 and –9 was assessed by RT-PCR due to the 
lack of suitable antibodies, while other proteins 
implicated in either effecting or inhibiting apoptosis 
were assessed by immunoblot. In addition, levels of 
caspase-2, which has recently been implicated as 
playing an essential initiating role in genotoxin-
dependent apoptosis [48], was also assessed (Figure 
2A). In no instance was there a detectable difference 
between the null and reconstituted cells indicating that 
the loss of p65 did not alter the expression of these 
death machinery components. To confirm that the cell-
death machinery was competent we utilized a cell-free 
system for quantitation of caspase activation. In this 
system caspases are activated by the addition of 
cytochrome  c, triggering Apaf-1-dependent activation 
of caspase-9 and -3 [49]. Therefore, to test the 
functionality of the death machinery, cytochrome c was 
added to S-100 extracts from p65 null or reconstituted 
cells and caspase activation was assessed. As shown in 
Figure 2B and C, extracts derived from both cell types 
were equally capable of caspase activation, 
demonstrating that p65 null cells retained functional 
death machinery downstream of cytochrome c (Figure 
2B and C). 
 
Cytochrome c release is impaired in p65 null cells 
 
The next step upstream in the p53-induced apoptotic 
pathway is mitochondrial release of cytochrome c, 
controlled by the interaction between Bcl-2 family 
members. Therefore, we compared the sub-cellular 
localization of cytochrome c  in  p65 null and 
reconstituted cells after etoposide and UV-irradiation.   
Morphological changes triggered by caspases during 
apoptosis make it very difficult to assess the sub-
cellular localization of proteins. To allow accurate 
quantitation of cells with cytoplasmic cytochrome c, the 
apoptotic consequences of cytochrome c release were 
prevented with the caspase inhibitor z-VAD-fmk. In 
reconstituted cells, both stimuli induced cytoplasmic 
localization of cytochrome c after 24 hr. treatment 
(Figure 3). The percentage of cells showing released 
cytochrome c was lower than the incidence of apoptosis 
shown in Figure 1B. However, in Figure 1B the 
percentage of apoptotic cells in the total population, 
both detached and attached, was assessed. While 
immuno-localization of cytochrome c was assessed only 
in those cells that remained attached to the culture 
Figure  1.  Apoptosis  resistance  in  p65  null  MEFs.  (A)
retrovirus‐mediated  reconstitution  of  p65  null  MEFs  with  p65
restores NF‐κB function as measured by EMSA. Wild type (wt),




genotoxin‐induced  apoptosis.  Cells  were  treated  with  10  µM
etoposide or 5 mJ UV‐irradiation for 18 hr. Floating and attached
cells were then collected and stained with propidium iodide (PI).




(p<0.05).  (C)  S‐100  extracts  from  p65  null  (vector)  and
reconstituted  cells  (p65)  treated  with  10  μM  etoposide  were
used  to  assess  caspase  activity  by  cleavage  (arbitrary
fluorescence  units  per  minute  [AFU/min])  of  the  fluorogenic
substrate,  Ac‐DEVD‐afc.  The  data  shown  represent  the  mean
and SEM of three independent experiments. 
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detected in this assay. In contrast, very few p65 null 
MEFs showed cytoplasmic cytochrome c localization in 
response to genotoxins. These results suggest that the 
absence of p65 impaired p53-dependent death at or 
before cytochrome c release from the mitochondria. 
 
Gene profiling of p65 null MEFs reveals lack of 
Noxa expression 
 
Since p65 is a transcription factor, we reasoned that 
there may be one or more genes whose expression is 
compromised in p65 null MEFs and whose function is 
necessary for p53-dependent death, most likely 
controlling cytochrome c release from mitochondria.  
 
Therefore, we compared the expression profile of p65 
null versus p65 reconstituted cells using gene 
microarray analyses. Strikingly, expression profiling 
revealed that one of the genes upregulated by p65 
expression was Noxa, a pro-apoptotic BH3-only protein 
of the Bcl-2 family [50] (Table 1). Previously, this 
protein was reported to be induced by p53 and to be 
required for p53-induced death by controlling 






























immediate study. Of the other Bcl-2 family members 
screened none belonged to the top most differentially 
regulated genes (ratio p65 reconstituted/null >1.7; Table 
1). To validate the microarray data RT-PCR assays 
were performed to compare the expression level of 
several other Bcl-2 family members and the ones not 
represented in the array. As shown in Figure 4A, Noxa 
expression was absent in p65 null cells but expression 
was restored by re-introducing p65 (Figure 4A). In 
contrast, expression of other Bcl-2 family member was 
not impaired in p65 null cells. Likewise, immunoblot 
analysis showed Bax expression was not altered by the 
p65 status of the cells (Figure 4A). To assess whether 
Noxa expression could be induced by genotoxins, levels 
of Noxa mRNA from etoposide or UV-irradiation 
treated p65 null and reconstituted cells were evaluated 
by Northern blot. Noxa mRNA could not be detected in 
untreated p65 null cells but was present in the p65 
reconstituted cells, consistent with the microarray 
analysis (Figure 4B). Moreover, Noxa mRNA 
expression could be induced by etoposide or UV-
treatment in the reconstituted cells but not in the p65 
null cells (Figure 4B). Thus, p65 is necessary for Noxa 
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dependent apoptosis [38, 51], however, it is not clear 
whether expression of Noxa is sufficient to explain 
sensitivity to genotoxic agents. To address this issue 
Noxa was re-introduced in p65 null cells by retroviral 
transfer. Expression of the exogenous Noxa was 
confirmed by Northern blot analysis (Figure 4C). As 
depicted in Figure 4C, reconstitution of Noxa 
expression was not sufficient to promote death; 
however, Noxa expressing cells were more sensitive to 
genotoxic treatment than control cells. Thus, expression 
of Noxa in p65 null cells restored sensitivity to 











































p53 is mutant in p65 null and reconstituted cells 
 
Noxa has been shown to be necessary for p53-
dependent death and its expression is indeed induced by 
p53 [38, 51].  MEFs and, particularly, transformed cell 
lines derived from MEFs, very frequently acquire 
mutations in the p53 tumour suppressor.  A trivial 
explanation of our data is that the p65 null cells but not 
the p65 reconstituted cells had acquired a p53 mutation 
during serial passage and immortalization, thus 
explaining the lower apoptotic sensitivity of p65 null 
cells to DNA damaging agents.  To test this possibility, 
the DNA sequence of the p53 gene from both p65 null 
and reconstituted cells was compared.  Both cell lines 
showed identical sequence for the p53 gene, excluding 
the possibility that a p53 mutation would explain the 
observed difference in sensitivity to genotoxins.   
However, these data revealed that p53 was mutant: 
there was a silent mutation at codon 82 (c to t at base 
246) and a missense mutation at codon 275 (c to g at 
base 824) that results in a Proline to Arginine 
substitution.  This position corresponds to codon 278 in 
human p53 within the DNA binding domain, an 
extremely well conserved region.  This particular 
Pro278Arg mutation has been found in human tumours 
although the functionality of this mutant had not been 
previously tested.  Moreover, no wild type allele was 
detected in our sequencing and Southern Blotting 
revealed that both p65 null and reconstituted cells had 
only one copy of p53 (data not shown).  
 
To test the function of this mutant p53 its ability to 
activate a reporter gene was tested.  Mutant p53 was 
first cloned from p65 null cells by RT-PCR.  To control 
for the activity of this mutant codon 275 was reverted to 
wild type by site directed mutagenesis. Mutant or wild 
type p53 was then expressed in the p53 null cell line 
SaOS-2 along with a PG13 p53-responsive reporter 
construct (Figure 5A) or the Noxa promoter -183 to 
+146 in front of the luciferase reporter gene construct 
(Figure 5B).  The data clearly showed that wild type 
p53 activated both the p53 reporter and the Noxa 
promoter reporter constructs while P275R mutant failed 
to do so.  Immunoblotting showed that this lack of 
activity could not be explained by differences in p53 
expression (Figure 5C).  Expression of a well known 
p53 target, p21, was also assessed by immunoblotting 
and again, while wild type p53 induced expression of 
p21, mutant p275R failed to do so (Figure 5C).  In 
further experiments the ability of the P275R mutation to 
interfere with wild type p53 was tested. However, no 
interference was observed (data not shown) indicating 
that the P275R mutation, unlike some other p53 










then  assessed  by  cleavage  (arbitrary  fluorescence  units  per
minute  [AFU/min])  of  the  fluorogenic  substrate,  Ac‐DEVD‐afc. 




   








































Thus p53 status cannot explain the difference in 
sensitivity of the p65 null cells and reconstituted.   
Moreover, genotoxin induced death and induction of 
Noxa expression in these cells is p53 independent. 
 
Control of Noxa expression and apoptosis induction 
by p73 
 
p73 is a member of the p53 family that has been shown 
to promote apoptosis and to activate p53 target genes 
through the p53 elements in their promoters [52-56].   
Recently, E1A activation of p73 and induction of Noxa 
expression in the absence of p53 in an osteosarcome 
cell line has been shown [57].  To assess whether Noxa 
can be induced by p73, a reporter approach was used.   
p73 expression vectors were transiently transfected into 
SaOS-2 cell line along with the Noxa promoter reporter.  
Both p73α and p73β activated the expression of the 
reporter and they also activated expression of the PG13 
p53 reporter (Figure 6A).  To test if p73 was activating 
the Noxa promoter through the p53 element, a mutant 
promoter was used were the p53 element had been 
eliminated.  Neither p73α nor p73β activated the 
expression of this reporter indicating that Noxa 
expression by p73 uses the p53 element in its promoter, 
consistent with previous reports.  As a control, p73 did 
not activate transcription of a NF-κB dependent reporter 
(Figure 6A).  A p73 inducible SaOS-2 cell line was also 
used to demonstrate Noxa reporter induction by p73.   
Induction of p73 expression by Doxicycline indeed 
activated Noxa reporter but failed to activate the mutant 
promoter for the p53 element (data not shown), thus 
corroborating that p73 controls Noxa promoter. 
 
Having confirmed that p73 can control Noxa promoter, 
we tested next if DNA damage can induce p73 in p65 
null and reconstituted cells.  Cells were treated with 
etoposide for 24 hr. and p73 levels assessed by immuno-
blotting. This revealed the induction of a 52 kDa. protein, 
consistent with the p73β isoform (Figure 6B).  While 
induction was seen in both cell types, the levels of p73 in 
the p65 reconstituted cells were markedly higher than in 
the p65 null cells.  p73 levels in etoposide treated p65 
null cells were comparable to basal levels in the reconsti-
tuted cells, which were significantly induced by 
etoposide treatment.    Figure 3. Cytochrome c release in p65 null cells. (A) p65
null (vector) and reconstituted cells were treated with 10 ￿M
etoposide or 5 mJ UV‐irradiation in the presence of the caspase
inhibitor,  zVAD‐fmk  (50  μM)  for  18  hr.  and  then  fixed  and
stained  with  a  specific  antibody  for  native  cytochrome  c.  An
Alexa Green coupled secondary antibody was used to reveal the
localization  of  cytochrome  c.  (B)  Results  are  expressed  as
percentage of cells showing cytosolic cytochrome c. 
 
Dominant negative p73β blocks genotoxin-induced 
apoptosis and Noxa expression 
 
The previous data suggest that the reason p65 null cells 
are less sensitive to DNA damage is the failure to 
induce sufficiently high levels of p73.  To test this 
possibility, a dominant negative form of p73β ( ΔN-
p73β) was expressed in the p65 reconstituted cells by 
retroviral transfer and the level of apoptosis following 
etoposide treatment determined.  Apoptosis induction, 
assessed both by hypodiploid DNA content (Figure 7A) 
and caspase activation (Figure 7B), showed that 
dominant negative p73β effectively blocked apoptosis.  
This result indicates that p73 activation is necessary for 
DNA damage-induced apoptosis in this context.  Over-
expression of wild type p73β in the p65 null cells, 
however, did not induce apoptosis.  Moreover, 
etoposide treatment of p65 null cells expressing wild 
type p73β did not cause apoptosis (Figure 7A and B), 
suggesting that although necessary, p73 expression was 
not sufficient for etoposide-induced apoptosis in the 
absence of p65.   
   















































We used Northern blotting in order to test whether p73β 
controls Noxa expression in p65 null cells.  As shown in 
Figure 7C, over-expression of wild type p73β did not 
restore Noxa expression in p65 null cells, even after 
etoposide treatment.  However, expression of a domi-




























































successfully blocked expression of Noxa in these cells 
and prevented Noxa induction by etoposide treatment.  
These results are in accordance with the effect of domi-
nant negative p73β expression in apoptosis induction 
indicating that Noxa expression is the key regulator of 
apoptosis induced by genotoxins in the absence of p65. 
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DNA damage-induced apoptosis has been reported to 
require NF-κB [15], although which step of the 
apoptotic process is NF-κB dependent and which 
gene(s) are involved was not known. To investigate this 
issue, we characterized p65-dependent apoptosis using 
p65 null MEFs, which are resistant to genotoxin-
induced apoptosis. These experiments uncovered a 
defect in the release of cytochrome c from 
mitochondria. We then performed expression profiling 
to identify candidate mediators of this effect.  Our 
microarray analysis showed that Noxa –which acts to 
trigger cytochrome c release and is a known DNA 
damage-induced gene– was missing in the absence of 
p65.  Noxa is a pro-apoptotic BH3-only member of the 
Bcl2 family that binds and blocks the anti-apoptotic 
function of Bcl-2 protein, thus promoting cytochrome c 
release from the mitochondria and death [38].   
Therefore, lack of Noxa expression was likely to 
explain the apoptotic defect in p65 null cells. 
Subsequent experiments confirmed that p65 was indeed 
required for genotoxin-dependent induction of Noxa 
mRNA. Importantly, re-introducing Noxa into p65 null 
cells sensitized them to apoptosis induced by genotoxic 
agents. Interestingly, despite Noxa being necessary for 
genotoxin-induced apoptosis, ectopic expression of 
Noxa alone did not induce apoptosis. These findings 
suggest that Noxa expression alone is not sufficient for 
cell death and other factors may be required. 
 
Noxa is known to be a transcriptional target of p53, a 
tumour suppressor that is activated by both oncogenes 
and genotoxic chemotherapeutic drugs.  The experi-
ments described in this work were performed using 
transformed and immortalized MEFs, which frequently 
acquire p53 mutations during cell culture.  Clearly, our 
interpretation would be invalidated if the p65 
reconstituted cells acquired a mutation that com-
promised p53 but the p65 null cells did not.  When we 
sequenced p53 we found that both cell types had 
identical p53 sequence, excluding the possibility that a  
differential p53 function explained the p65 resistant 
phenotype.  However, p53 had acquired two mutations, 
a silent mutation in codon 82 and a substitution in 
codon 275, from Proline to Arginine.  This position is 
within the DNA binding domain of p53 and corresponds 
to P278R in human p53, a mutation that is found in a 
subset of human tumours.  The effect on p53 function of 
this mutation was unknown. Our analysis showed that 
this mutation compromised p53 ability to transactivate 
target genes, including Noxa.  Therefore p53 is not 



































(as  control).  48  hr.  after  transfection  luciferase  activity  was
compared.  Results are expressed as fold induction above mock
(empty pcDNA3 vector) control.  (B) p73 activation in p65 null
and  reconstituted  cells.  Cells  were  treated  with  10  μM














p63 and p73 are proteins functionally and structurally 
related to p53, constituting a family of related 
transcription factors.  The overall structure of the three 
proteins is quite similar, producing remarkably similar 
effects when over-expressed in cells [58, 59].  E1A 
transformed MEFs deficient in both p63 and p73 are 
resistant to genotoxin-induced apoptosis, even in the 
presence of p53, therefore suggesting that these three 
genes might act together or p63/p73 act in an 
independent pathway to activate DNA damage-induced 
apoptosis [60].  Moreover, p73 activation is induced by 
a subset of DNA damaging drugs and blocking its 
function with a dominant negative mutant or siRNA led  
to apoptosis resistance of transformed human cell lines,  
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can induce apoptosis suggesting a pro-apoptotic role on 
its own.  Several of the p53 dependent genes involved 
in apoptosis have been demonstrated to be significantly 
regulated by p73, such as Bax, DR5 and PUMA [52], 
and p53 binding to the promoters of its pro-apoptotic 
targets PERP, Noxa and Bax required the presence of 
p73 and/or p63 [60].  Moreover, Noxa was recently 
shown to be a p73 target to trigger E1A-induced 













































investigated the role of p73 in DNA damage-induced 
apoptosis in the p65 null cells.  Our data showed that 
activation of p73 by genotoxins was compromised in 
the absence of p65.  By using a dominant negative p73 
mutant we demonstrated that genotoxin-induced 
apoptosis relies on p73 activation and importantly, that 
p73 activation is required for Noxa expression in our 
cells.  We also provide, for the first time, formal proof 
that Noxa is regulated by p73 at the promoter level 
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NF-κB transcription factor is widely accepted as an 
anti-apoptotic factor [62] and several anti-apoptotic 
genes (for review see [22]) are known to be activated by 
NF-κB following treatment with TNFα. Moreover, the 
embryonic lethality in p65 knock-out mice is caused by 
extensive TNFα induced apoptosis in the liver [63].   
NF-κB activation in tumor cell lines by chemotherapy 
has been reported and inhibition of NF-κB activation 
can enhance apoptosis induced by chemotherapy in a 
xenograft model of tumorigenesis [64, 65]. These are 
strong data consistent with an anti-apoptotic role for 
NF-κB.  However, in other situations NF-κB appears to 
be pro-apoptotic [15-17, 31-34, 66]. As suggested by 
Blagosklonny [67], cellular responses should be defined 
in molecular terms where the same signalling pathways 
may participate in different, and often contradictory, 
end-points (in our case, induction of apoptosis vs. 
survival). Upstream signaling is initiated simultaneously  
and the cell translates it according to cellular context. 
Therefore NF-κB may act as a stress response 
transcription factor whose effect on a cell is context–
dependent.  There may also be mechanistic differences 
between the pro-apoptotic activity and anti-apoptotic 
activity of NF-κB; suppression of steady state but not 
stimulus-induced NF-κB activity inhibits Alphavirus-
induced apoptosis [68].  This is consistent with our 
observations that TNFα, a well-known activator of NF-
κB through the canonical pathway, had no effect on 
Noxa expression, even though a NF-κB control reporter 
was activated (data not shown).   
 
In our system, the pro-apoptotic effect of NF-κB 
depends on the activation of p73.  How this is 
accomplished is not clear.  p73 activation is mediated in 
part by protein stabilization, as it is for p53, since 
proteasome inhibitors stabilize the protein [69].  In 
contrast to p53, however, p73 degradation is not 
mediated by MDM2, although p73 binds to MDM2 and 
blocks its transcription promoting activity.  p73 
stabilization and activation by genotoxic stress is also 
associated with p73 phosphorylation.  Several kinases 
have been implicated in this step. Thus following γ-
irradiation c-Abl phosphorylates p73 at Tyr99 activating 
p73 and inducing apoptosis [70, 71]. Phosphorylation at 
Tyr120 and Tyr240 were also shown [72].  The 
checkpoint kinases, CHK1 and CHK2, which are 
activated following DNA damage may also play a role, 
controlling p73 mRNA induction [73]. Aurora Kinase A 
regulates p73 dependent apoptosis in p53 deficient cell 
lines [74].  It is possible that absence of p65 DNA 
damage fails to activate p73 because the activity of one 
or all of these kinases is compromised in the absence of 
p65.  We showed that ectopic expression of p73β alone 
in the absence of p65 was not sufficient to reinstate 
expression of Noxa or restore apoptosis sensitivity.  
These data indicate that the absence of p65 
compromises other steps in genotoxin-induced 
apoptosis in addition to p73. The simplest model is that 
p65 is required for the DNA-damage induced signalling 
pathways upstream of p73.  
 
Since inhibition of NF-κB is currently being explored as 
a way of potentiating anti-cancer therapy [21, 75] it is 
essential to define specifically where and when NF-κB 
shows a preferentially pro- or anti-apoptotic face. The 
observation that NF-κB controls expression of Noxa in 
the absence of functional p53, and loss of p53 function 
occurs in >50% of human tumours, suggests that in 
some contexts inhibition of NF-κB may compromise, 
rather than enhance, the efficacy of conventional anti-
cancer therapy.  
 
MATERIALS AND METHODS 
 
Plasmids, reagents and antibodies. Murine p65 was 
cloned into the EcoRI site in the retroviral vector 
pWZL-Hygro.  Murine Noxa was cloned from cDNA 
made from p65 reconstituted MEFs as a HA tagged 
fusion gene into the BamHI/EcoRI site of pcDNA3.1+ 
and the retroviral vectors pWZL-Blast and pBabe-Puro. 
Mutant P275R p53 was obtained by RT-PCR from 
immortalized p65 null cells and cloned directly into 
pcDNA3-TOPO (Invitrogen).  Wild type p53 was 
generated by reverting the P275R mutation using the 
Quick-change site directed mutagenesis kit (Stratagene) 
following manufacturer’s instructions. Expression 
vectors for p73α, DN-p73α, p73β and DN-p73β were 
kindly provided by Prof. G. Melino (University of 
Leicester, UK) and were subcloned into pWZLBlast 
retroviral vector.  Recombinant mouse tumor necrosis 
factor  α (TNFα) and etoposide were purchased from 
Sigma. For immuno-blotting we used antibodies against 
human Noxa (Imgenex), Bax, caspase 2, p21 (Santa 
Cruz Biotechnology), anti-HA (kindly provided by Dr 
P. Kaldis, NCI-Frederick, Frederick, MD), Apaf-1 
(Alexis), cytochrome c (BD-Pharmingen), ￿-actin 
(Abcam), XIAP (BD-Transduction Laboratories), p53 
(supernatant from culture of the DO-1 hybridoma), p73 
(provided by Prof. G. Melino, University of Leicester, 
UK) and p65 (kindly provided by Dr N. Rice, NCI-
Frederick, Frederick, MD). 
 
Cells, transfection and retroviral gene transfer. Mouse 
fibroblasts and human cancer cells were grown in 
Dulbecco’s modified minimal essential medium 
(DMEM, Gibco) supplemented with 10% fetal bovine 
serum (FBS, Gibco) at 37 °C in 10% CO2. Cells were 
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in accordance with the manufacturer’s instructions and 
washed after 3 hr. incubation before adding fresh 
DMEM+10% FBS and incubating for a further 18 hr. 
For retoviral transfer, viral vectors were transfected into 
the Phi-NX ecotropic packaging cell line and after 24 
hr. the transfection culture medium was filtered and 
added to p65 null MEFs.  Infected cells were selected 
using the appropriate antibiotic. 
 
Electro-Mobility Shift Assay (EMSA). Preparation of 
nuclear extracts was previously described [35]. The 
binding reaction consisted of 10 µg of extracted nuclear 
protein and 5 µg of poly dI-dC (Roche) in a total 
reaction volume of 10 µl containing 6 mM MgCl2. This 
mixture was then incubated at room temperature for 10 
minutes, after which 2 μl (50,000 cpm) of the NF-κB 
consensus oligonucleotide (Promega), end-labeled with 
[
32P]-γ-ATP (specific activity = 3,000 Ci/mmol; 
Amersham), was added. A control reaction mixture 
containing a 100-fold molar excess of non-radioactive 
NF-κB oligonucleotide was used to verify the 
specificity of the binding reaction. After incubation at 
4˚C for 15 minutes the reaction mixtures were run on a 
5% PAGE. After drying, the gels were subjected to 
autoradiography. 
 
Extract preparation and caspase activity assay. 2 x 10
8 
p65 and reconstituted MEFs were used to prepare S-100 
extracts as described [36].  Briefly, cells were harvested 
by trypsinization and washed in PBS. Cells were 
resuspended in 10 ml of extract buffer (50 mM PIPES, 
pH 7.0, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 
mM DTT, 2 µg/ml each of Leupeptin, Chymostatin, 
Antipain and Pepstatin A, 10 µg/ml Cytochalasin B and 
100 µM PMSF), centrifuged and excess buffer 
immediately removed. Cells were then lysed by three 
freeze-thaw cycles in liquid nitrogen and centrifuged at 
100,000 x g for 60 minutes to obtain an S-100 extract 
(≈30 mg/ml protein by Bradford assay). For caspase 
activity assessment, 30 μg of cell extract were used to 
determine conversion of the fluorogenic caspase 
substrate Ac-DEVD-afc (Biomol).  For caspase 
activation, equine cytochrome c (1 μM; Sigma) was 
added and extracts incubated at 37 ˚C for 60 minutes 
with 1 mM ATP as indicated. After this time caspase 
activity was determined using a Cytoflour 2000 
flourimeter. 
 
Cytochrome  c immuno-localization. p65 null and 
reconstituted MEFs were grown on glass coverslips 
prior to treatment with etoposide (10 μM) or UV-
irradiation (5 mJ). 18 hr. later cells were fixed in 2% 
formaldehyde and permeabilized with 0.2% Triton. 
Fixed cells were incubated with an anti-native 
cytochrome c antibody. A secondary antibody coupled 
to Alexa Green (Molecular Probes) was used to detect 
cytochrome c. 
 
Flow cytometry. Floating cells were recovered and 
pooled with adherent cells harvested by trypsinization. 
Cells were resuspended in PBS containing 1% Triton, 
50 µg/ml propidium iodide, and 100 µg/ml RNase A 
and stained for 30 minutes. After this time the 
percentage of cells with sub-G1 DNA content was 
determined by flow cytometry. 
 
Microarray analysis. Total mRNA from p65 null and 
reconstituted MEFs was amplified and labeled with 
Cyanine 3 (Cy3) or Cyanine 5 (Cy5) dUTP, essentially 
as described [37] and used for microarray hybridization 
onto cDNA microarrays. These arrays were 
manufactured at the NCI Microarray Facility 
(Frederick, MD) by spotting UniGene mouse cDNA 
clones (Incyte Genomics) onto glass slides. Data was 
collected on an Axon scanner where Cy3 and Cy5 
fluorescence was measured and compared. Results were 
expressed as ratio of Cy3 to Cy5 for each experiment. 
The data shown are averages from 5 independent arrays. 
 
RT-PCR and Northern Blot. Total RNA from p65 null 
and reconstituted MEFs was obtained using Trizol 
(Gibco BRL) following the manufacturer’s instructions. 
For RT-PCR 1 μg of RNA was used to generate cDNA 
using the GeneAmp RNA PCR kit (Perkin Elmer) 
which was then used to amplify the corresponding 
genes with specific oligonucleotides. The coding 
sequence amplified for each gene were; caspase-3, 62-
772; caspase-9, 205-1264; GAPDH, 339-865; Bcl-X, 
122-487; A1, 133-387, Bcl-w, 65-503, Bok, 50-482; 
Bak, 31-585, Noxa(CDS), 1-312; Noxa (probe 1), 1-
1040; Noxa (probe 2) 1230-1832; Bmf, 81-434; Bad, 
109-366; Hrk, 1-242; Bim, 33-306; Bid, 32-292; 
PUMA, 85-485; and Bik, 120-399. 
 
For Northern blot 10 μg of RNA was loaded per lane 
onto a 1% agarose-formaldehyde gel. The RNA was 
transferred to Hybond-N+ membranes (Amersham 
Pharmacia) and hybridized with [
32P]-labeled cDNA 
probes using ExpressHyb Hybridization solution 
(Clontech) following the manufacturer's instructions. 
The Noxa probe was generated as a PCR fragment from 
the mRNA extending from 1 to 1040. PUMA probe was 
generated by PCR amplification of the 85-485 fragment 
of mouse mRNA. GAPDH probe was purchased from 
SeeGene.   
 
Luciferase assays. For reporter assays, Saos-2 p53 Tet-
on cells were transfected with 0.5 μg of luciferase 
reporter and varying amounts of the appropriate 
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according to manufacturer’s instructions. The Noxa 
reporter was made placing the –183 to +149 
(SacII/SacII) fragment of the murine Noxa promoter 
[38] in the SmaI site in pGL3-Basic (Promega).  PG13-
Luc, containing a generic p53 response element [39] 
and NF3TK-Luc, containing a trimer of the NF-kB site 
in the H2-k promoter [40], were also used.  Cells were 
harvested 48 hr. after transfection and luciferase activity 
was measured in duplicate with the Optocomp II 
luminometer (MGM Instruments) using 20 μl cell 
lysate, 100 μl substrate injection and 10 second count 
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